Category : Healthcare and Pharmaceuticals | Published at : January-2019 | Delivery Format : PDF | Status: Published | Pages : 160
The global vaginitis therapeutics market size is anticipated to around USD 4.5 billion by 2026, this market is anticipated to grow with 9.0% CAGR during the forecast time period.
Market Dynamics
Expanding mindfulness about ladies' wellbeing, introduction of new medications by key organizations, and rising need for improved healthcare infrastructure are a portion of the main considerations driving the market.
As per the Centers for Disease Control and Prevention (CDC), in 2015, more than 13 of each 100 ladies were cigarette smokers. The National Institute of Allergy and Infectious Diseases (NIAID) supported researchers to build up the test for yeast contamination in order to give suitable enemy of parasitic treatment. Likewise, NICHD specialists inside the Division of Intramural Population Health inquire about (DIPHR) are utilizing past and recently gathered information to investigate different parts of relationship between bacterial vaginosis and pregnancy result.
Market Insights
Based on type, market is segmented into Over-The-Counter (OTC) and prescription (Rx). Among these, prescribed type represents the larger market share of the overall industry owing to higher effectiveness and safety for severe and recurring vaginitis. OTC is relied upon to extend at a CAGR of 8.7% during the coming years because of the nearness of wide scope of OTC medications, for example, vaginal creams, gels, and others. Besides, for non-prescribed drugs, FDA has affirmed treatment alternatives for gentle vaginitis for outside use. These incorporate tioconazole miconazole, clotrimazole, and butoconazole as cream, tablets, and suppositories.
Based on product, vaginitis therapeutics market is bifurcated into anti-fungal, anti-bacterial, and hormone. Anti-bacterial segment capture the largest market share due to increasing cases of bacterial vaginosis. This segment was valued at USD 990 million in 2018, in terms of revenue. It was reported that about 21 million women were suffering from this disease. Drugs used for the treatment of clindamycin, bacterial vaginosis metronidazole, and tinidazole.
Market Segmentation
Market By Product
- Anti-fungal
- Anti-bacterial
- Hormone
Market By Type
- Over-The-Counter (OTC)
- Prescription (Rx)
Market By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Regional Insights
North America drove the worldwide market in 2017 and was esteemed at USD 861.2 million. Set up healthcare infrastructure in this region alongside occurrence of key producers is a main parameters responsible for its largest share. Different components, for example, good government activities and developing target populace are likewise pushing the market development.
Asia Pacific is evaluated to observe the quickest development with CAGR of around 9.6% during the coming years. This is credited to high neglected clinical necessities, rising disposable income and expanded mindfulness about early conclusion, and accessibility of powerful medications in rising nations, for example, India and China.
Market Participants
Market companies are concentrating on implementing new strategies for instance regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. The major players associated with thevaginitis therapeutics areMission Pharmacal Company, Pfizer, Inc., Symbiomix Therapeutics, Inc., Novartis AG, Merck & Co., Lupin Pharmaceuticals, Inc., and Bayer AG.
